Literature DB >> 19570861

A function essential to viral entry underlies the hepatitis B virus "a" determinant.

Jessica Salisse1, Camille Sureau.   

Abstract

The hepatitis B virus (HBV) particles bear a receptor-binding site located in the pre-S1 domain of the large HBV envelope protein. Using the hepatitis delta virus (HDV) as a surrogate of HBV, a second infectivity determinant was recently identified in the envelope proteins antigenic loop (AGL), and its activity was shown to depend upon cysteine residues that are essential for the structure of the HBV immunodominant "a" determinant. Here, an alanine-scanning mutagenesis approach was used to precisely map the AGL infectivity determinant to a set of conserved residues, which are predicted to cluster together with cysteines in the AGL disulfide bridges network. Several substitutions suppressed both infectivity and the "a" determinant, whereas others were infectivity deficient with only a partial impact on antigenicity. Interestingly, G145R, a substitution often arising under immune pressure selection and detrimental to the "a" determinant, had no effect on infectivity. Altogether, these findings indicate that the AGL infectivity determinant is closely related to, yet separable from, the "a" determinant. Finally, a selection of HDV entry-deficient mutations were introduced at the surface of HBV virions and shown to also abrogate infection in the HBV model. Therefore, a function can at last be assigned to the orphan "a" determinant, the first-discovered marker of HBV infection. The characterization of the AGL functions at viral entry may lead to novel approaches in the development of antivirals against HBV.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19570861      PMCID: PMC2738268          DOI: 10.1128/JVI.00678-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

Review 1.  Hepatitis B virus infection--natural history and clinical consequences.

Authors:  Don Ganem; Alfred M Prince
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

2.  Sequence comparison of woodchuck hepatitis virus replicative forms shows conservation of the genome.

Authors:  J I Cohen; R H Miller; B Rosenblum; K Denniston; J L Gerin; R H Purcell
Journal:  Virology       Date:  1988-01       Impact factor: 3.616

3.  Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides.

Authors:  S E Brown; C R Howard; A J Zuckerman; M W Steward
Journal:  Lancet       Date:  1984-07-28       Impact factor: 79.321

4.  Mutations in S region of hepatitis B virus.

Authors:  A J Zuckerman; T J Harrison; C J Oon
Journal:  Lancet       Date:  1994-03-19       Impact factor: 79.321

5.  Infection of a human hepatoma cell line by hepatitis B virus.

Authors:  Philippe Gripon; Sylvie Rumin; Stephan Urban; Jacques Le Seyec; Denise Glaise; Isabelle Cannie; Claire Guyomard; Josette Lucas; Christian Trepo; Christiane Guguen-Guillouzo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-13       Impact factor: 11.205

6.  Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein.

Authors:  C M Mangold; R E Streeck
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response.

Authors:  J A Waters; S E Brown; M W Steward; C R Howard; H C Thomas
Journal:  Virus Res       Date:  1992-01       Impact factor: 3.303

Review 8.  The global impact of vaccination against hepatitis B: a historical overview.

Authors:  Alessandro R Zanetti; Pierre Van Damme; Daniel Shouval
Journal:  Vaccine       Date:  2008-10-09       Impact factor: 3.641

9.  Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope.

Authors:  F Bonino; K H Heermann; M Rizzetto; W H Gerlich
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

10.  A novel hepatitis B virus variant in the sera of immunized children.

Authors:  V D Karthigesu; L M Allison; M Fortuin; M Mendy; H C Whittle; C R Howard
Journal:  J Gen Virol       Date:  1994-02       Impact factor: 3.891

View more
  43 in total

Review 1.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

2.  Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection.

Authors:  Subhajit Biswas; Daniel Candotti; Jean-Pierre Allain
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

3.  Protein-peptide arrays for detection of specific anti-hepatitis D virus (HDV) genotype 1, 6, and 8 antibodies among HDV-infected patients by surface plasmon resonance imaging.

Authors:  Marie-Bernadette Villiers; Jean-Claude Cortay; Sandra Cortès; Bénédicte Bloquel; Ségolène Brichler; Carine Brakha; Alan Kay; Nisrine Falah; Fabien Zoulim; Christophe Marquette; Patrice N Marche; Paul Dény
Journal:  J Clin Microbiol       Date:  2015-01-28       Impact factor: 5.948

Review 4.  Living in the liver: hepatic infections.

Authors:  Ulrike Protzer; Mala K Maini; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2012-02-24       Impact factor: 53.106

5.  HBV life cycle is restricted in mouse hepatocytes expressing human NTCP.

Authors:  Hanjie Li; Qiuyu Zhuang; Yuze Wang; Tianying Zhang; Jinghua Zhao; Yali Zhang; Junfang Zhang; Yi Lin; Quan Yuan; Ningshao Xia; Jiahuai Han
Journal:  Cell Mol Immunol       Date:  2014-02-10       Impact factor: 11.530

6.  Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes.

Authors:  Jan Felix Drexler; Andreas Geipel; Alexander König; Victor M Corman; Debby van Riel; Lonneke M Leijten; Corinna M Bremer; Andrea Rasche; Veronika M Cottontail; Gael D Maganga; Mathias Schlegel; Marcel A Müller; Alexander Adam; Stefan M Klose; Aroldo José Borges Carneiro; Andreas Stöcker; Carlos Roberto Franke; Florian Gloza-Rausch; Joachim Geyer; Augustina Annan; Yaw Adu-Sarkodie; Samuel Oppong; Tabea Binger; Peter Vallo; Marco Tschapka; Rainer G Ulrich; Wolfram H Gerlich; Eric Leroy; Thijs Kuiken; Dieter Glebe; Christian Drosten
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

7.  Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction.

Authors:  Andreas Schulze; Alexa Schieck; Yi Ni; Walter Mier; Stephan Urban
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

8.  Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation.

Authors:  Karen Kwei; Xiaoli Tang; Anna S Lok; Camille Sureau; Tamako Garcia; Jisu Li; Jack Wands; Shuping Tong
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

Review 9.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

10.  Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide.

Authors:  Huan Yan; Bo Peng; Wenhui He; Guocai Zhong; Yonghe Qi; Bijie Ren; Zhenchao Gao; Zhiyi Jing; Mei Song; Guangwei Xu; Jianhua Sui; Wenhui Li
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.